FDA accepts Amgen’s sBLA for expanded use of Enbrel drug
The sBLA is based on results from a phase 3 one-year study and its five-year open-label extension trial to assess the safety and efficacy of Enbrel in pediatric
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
That’s why researchers at Hennepin County Medical Center (Minneapolis, Minn.) and the University of Minnesota are launching an innovative, comprehensive study in collaboration with Abbott (NYSE: ABT) to